A randomized controlled trial of subcutaneous apomorphine for Parkinson disease: A repeat dose and pharmacokinetic study

Clinical Neuropharmacology

Volumn 38, Issue 6, 2015, Pages 241-247

  Nomoto, Masahiro ^a   Kubo, Shin Ichiro ^b   Nagai, Masahiro ^a   Yamada, Tatsuo ^c   Tamaoka, Akira ^d   Tsuboi, Yoshio ^e   Hattori, Nobutaka ^b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Orthopaedic Surgery   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e FUKUOKA UNIVERSITY   (Japan)

Author keywords

Apomorphine; Clinical trial; Parkinson disease

Indexed keywords

ALANINE AMINOTRANSFERASE; APOMORPHINE; ASPARTATE AMINOTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CREATINE KINASE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO;

ADULT; APPLICATION SITE ERYTHEMA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FALLING; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; THIRST; UNIFIED PARKINSON DISEASE RATING SCALE; YAWNING; AGED; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; JAPAN; MIDDLE AGED; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR;

AGED; APOMORPHINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; JAPAN; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84947867772     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000111     Document Type: Article

References (11)

1. Dewey RB Jr, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385-1392.
2. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58:681-687.
3. Van Laar T, Jansen EN, Essink AW, et al. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin Neurol Neurosurg 1993;95:231-235.
4. LeWitt PA, OndoWG, Van Lunen B, et al. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off " episodes in advanced Parkinson disease. Clin Neuropharmacol 2009;32:89-93.
5. Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007;258:137-143.
6. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
7. Grandas F, Gancher S, Lera G, et al. Time interval between repeated injections conditions the duration ofmotor improvement to apomorphine in Parkinson's disease. Neurology 1992;42:1287-1290.
8. Hughes AJ,Webster R, BovingdonM, et al. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. Clin Neuropharmacol 1991;14:556-561.
9. Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-1950.
10. US WorldMeds, LLC. Apokyn® (apomorhine hydrochloride injection) prescribing information. February 2012. USWorldMeds ApokynWeb site. Available at: http://www.apokyn.com/assets/APOKYN-PI.pdf. Accessed November 14, 2012.
11. Hattori N, Nomoto M, 6500-004 Study Group. Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2014;20:819-823.